List view / Grid view
Knowledge is power – for scientists at least – and thanks to collaborative research from a UK and German university, we now have better understanding of the SARS-CoV-2 Omicron virus, including how it behaves and effective means of treatment.
In mice, researchers have shown that δ-valerobetaine plays a role in neurocognitive ability, making the metabolite a target for age-related memory loss.
Researchers have developed a new drug delivery system using virus-like particles to successfully transport gene-editing proteins in pre-clinical studies.
Avacta Group announced that the chemotherapy candidate AVA3996 will be developed with a view to a first-in-human clinical trial beginning in 2023.
Representing a breakthrough in better understanding how tau proteins cause neurodegenerative disease, scientists have mapped the tau interactome.
Using cryo-electron microscopy, researchers have completed the world’s first molecular analysis of the SARS-CoV-2 Omicron spike protein.
Janssen's monoclonal antibody CR9114, for the potential treatment of influenza, has been exclusively licensed by Leyden Labs for development and commercialisation.
Research has shown that memory T cells formed following SARS-CoV-2 infection or mRNA vaccination respond to the Omicron variant.
Japanese researchers have formed ordered biological structures using protein needles, enabling protein self-assembly into lattice structures.
New Bristol Myers Squibb research has revealed details about the structure of the protein receptor CD47, which helps protect cells from the human immune system.
Urea cycle disorders affect the liver’s ability to excrete urea from the body. To test potential therapeutics requires an accurate model – a hurdle that has now been successfully navigated thanks to a team of researchers in Switzerland.
Researchers have developed rapamycin-loaded nanocarriers capable of targeting cells related to pancreatic islet transplants without suppressing wider immune responses.
Sino Biological has announced that its new location in Houston, Texas, is now open, expanding the company geographically.
Researchers have shown that twisted nanoscale semiconductors can be utilised to accelerate the discovery of drugs through high-throughput screening.
During investigations into the tropical disease Buruli ulcer, researchers have instead identified a promising new avenue for potential treatments for multiple myeloma.
